糖尿病与认知功能障碍
摘要
目的:研究年龄相对较轻糖尿病患者和非糖尿病患者蒙特利尔认知评估(Montreal cognitive assessment,MoCA)评分是否相同,并进一步分析糖尿病患者及非糖尿病患者大脑海马波谱磁共振(Magnetic Resonance Spectroscopy,MRS),来观察糖尿病患者和非糖尿病患者分子水平对认知功能的影响,并进一步研究胰岛素分泌、药物治疗对认知功能的影响。
方法:选择本院39例糖尿病患者作为病例组,39例非糖尿病患者作为对照组,进行性别、年龄、教育水平等配对,对照组进行简易精神状态检查法(mini mental state examination,MMSE)、HAD、MoCA评分并进行头颅磁共振海马部位MRS分析,病例组除进行MMSE、HAD、MoCA评分、头颅海马部位MRS分析外,还记录其胰岛素分泌状态即C-肽空腹状态下分泌量、治疗情况等。
对评定和记录的结果进行记录整理,剔除不符合要求者或中途退出检查者。
对病例组和对照组分别进行可比性分析、MMSE、HAD评分比较分析、MoCA评分总分及各项评分比较分析,对病例组和对照组进行头颅MRS所测代谢物质进行数据处理,对海马组织代谢物质进行比较分析。
对病例组按照治疗情况和胰岛素分泌功能进行再次分组,并再次进行MoCA评分分析和MRS分析,以评估分析药物治疗和胰岛素功能对认知评分和海马代谢物质的影响。
结果:(1)病例组和对照组性别、年龄、教育水平、HAD无明显差异,MMSE评分出现封顶效应。病例组视空间、命名、计算、抽象、注意、语言、延迟回忆、定向和总分低于对照组。其中视空间、注意、计算、语言、抽象、延迟回忆及总分明显低于正常对照组(p<0.01),而病例组和对照组海马MRS统计分析显示:左侧Cho(Choline,Cho)( p=.012<0.05)、左侧NAA(N-acetylaspartate,NAA) (p=.008<0.01)、右侧Cho (p= .033<0.05)右侧NAA (p=.034<0.05)有差异,其中左侧NAA在病例组和对照组中有显著差异。(2)按照胰岛素分泌功能取值C-肽为0.3为临界点分病例组为胰岛素分泌正常组和胰岛素分泌功能减退组,对这两组病人进行MOCA和MRS进行比较发现,两者在性别、年龄和教育水平上没有明显差异,MoCA评分中定向力有差异(p=.012<0.05),MRS评分未见有差异性。(3)对病例组按照治疗情况(未进行任何治疗的初发组、药物治疗组、胰岛素治疗组)进行分组发现各组之间认知功能评分无明显差异。这可能和病例选择、病例人数、选择偏移等有关。结论:糖尿病患者有较早期的认知功能受损,这种认知功能受损和糖尿病患者血糖代谢和胰岛素分泌有关,并在海马MRS上有早期的代谢物质异常表现。
Objective :To investigatethe cognitive between diabetes and non diabetes with Montreal cognitive assessment, and then analyze those two groups of people with Magnetic Resonance Spectroscopy on brain hippocampus. So we can overview the effection between diabetes and non-diabetes on molecular level,furthe more to study how insulin secretion、drug treat effect cognition.
Methods: chose 39 diabetes and 39 normal people as research object with the mach of sex,ges,ducation levels and so on. Then do MMSE ( mini mental state examination),AD,oCA test,rain hippocampus MRS.And also the diabetes will do C- peptide text,rug therapeutics conditions and so on.
With all those evaluations and records,we do some sorting,rejecting the mismatch or exiter halfway.
Make comparability analyses with the two group,MSE and HAD comparison analyses,oCA total score and each item comparison analyses. Do some data processing at brain hippocampus MRS,make some metabolins comparison analyses.
Do the diabetes further grouping according to drug treatment condition and insulin secretion,and carry out MoCA and brain hippocampus MRS analyze,to evaluate cognition effected by drug treatment and insulin secretion function.
Results:(1)There is no significant different in sex,ge,ducational level,AD between the cases and the control group,but MMSE score appearants polarization. The cases are lower than the control group in Vis-vacuity,enomination,alculation,bstract,ttention,anguage,elay reminiscence,direction location and total score. Among the total, there are significant lower than the control group such as Vis-vacuity,enomination,alculation,bstract,elay reminiscence and total score(p<0.01). there are some diversity between the cases and the control group at the hippocampus MRS in left Cho( p=.012<0.05),AA(p=.008<0.01),right Cho (p= .033<0.05),AA (p=.034<0.05),of all the above contents, left NAA apparent significantly different between the cases and the control group. (2)According to insulin secretion function take C-peptide 0.3 as breakthrough,and then to divide the diabetes insulin secretion normal group and insulin secretion abnormal group, then make comparison with MOCA and MRS those two group, we found that there is no different in sex,age,education level about those two group,but they are diversity in orientation force with MoCA, there is also no different in MRS. (3)According to drug treatment condition(non treatment,drug treatment,insulin treatment) we found that there is no significant difference.Maybe this outcome have something with the cases selection,quantity,selection offset and so on.
Conclusion:there is a pristine cognition damage comparatively, and the cognition damage have something to do with blood glycometabolism and insulin secretion in diabetes, also it can reflected with implement MRS,we can found that there is abnormal metabolin in brain.
方法:选择本院39例糖尿病患者作为病例组,39例非糖尿病患者作为对照组,进行性别、年龄、教育水平等配对,对照组进行简易精神状态检查法(mini mental state examination,MMSE)、HAD、MoCA评分并进行头颅磁共振海马部位MRS分析,病例组除进行MMSE、HAD、MoCA评分、头颅海马部位MRS分析外,还记录其胰岛素分泌状态即C-肽空腹状态下分泌量、治疗情况等。
对评定和记录的结果进行记录整理,剔除不符合要求者或中途退出检查者。
对病例组和对照组分别进行可比性分析、MMSE、HAD评分比较分析、MoCA评分总分及各项评分比较分析,对病例组和对照组进行头颅MRS所测代谢物质进行数据处理,对海马组织代谢物质进行比较分析。
对病例组按照治疗情况和胰岛素分泌功能进行再次分组,并再次进行MoCA评分分析和MRS分析,以评估分析药物治疗和胰岛素功能对认知评分和海马代谢物质的影响。
结果:(1)病例组和对照组性别、年龄、教育水平、HAD无明显差异,MMSE评分出现封顶效应。病例组视空间、命名、计算、抽象、注意、语言、延迟回忆、定向和总分低于对照组。其中视空间、注意、计算、语言、抽象、延迟回忆及总分明显低于正常对照组(p<0.01),而病例组和对照组海马MRS统计分析显示:左侧Cho(Choline,Cho)( p=.012<0.05)、左侧NAA(N-acetylaspartate,NAA) (p=.008<0.01)、右侧Cho (p= .033<0.05)右侧NAA (p=.034<0.05)有差异,其中左侧NAA在病例组和对照组中有显著差异。(2)按照胰岛素分泌功能取值C-肽为0.3为临界点分病例组为胰岛素分泌正常组和胰岛素分泌功能减退组,对这两组病人进行MOCA和MRS进行比较发现,两者在性别、年龄和教育水平上没有明显差异,MoCA评分中定向力有差异(p=.012<0.05),MRS评分未见有差异性。(3)对病例组按照治疗情况(未进行任何治疗的初发组、药物治疗组、胰岛素治疗组)进行分组发现各组之间认知功能评分无明显差异。这可能和病例选择、病例人数、选择偏移等有关。结论:糖尿病患者有较早期的认知功能受损,这种认知功能受损和糖尿病患者血糖代谢和胰岛素分泌有关,并在海马MRS上有早期的代谢物质异常表现。
Objective :To investigatethe cognitive between diabetes and non diabetes with Montreal cognitive assessment, and then analyze those two groups of people with Magnetic Resonance Spectroscopy on brain hippocampus. So we can overview the effection between diabetes and non-diabetes on molecular level,furthe more to study how insulin secretion、drug treat effect cognition.
Methods: chose 39 diabetes and 39 normal people as research object with the mach of sex,ges,ducation levels and so on. Then do MMSE ( mini mental state examination),AD,oCA test,rain hippocampus MRS.And also the diabetes will do C- peptide text,rug therapeutics conditions and so on.
With all those evaluations and records,we do some sorting,rejecting the mismatch or exiter halfway.
Make comparability analyses with the two group,MSE and HAD comparison analyses,oCA total score and each item comparison analyses. Do some data processing at brain hippocampus MRS,make some metabolins comparison analyses.
Do the diabetes further grouping according to drug treatment condition and insulin secretion,and carry out MoCA and brain hippocampus MRS analyze,to evaluate cognition effected by drug treatment and insulin secretion function.
Results:(1)There is no significant different in sex,ge,ducational level,AD between the cases and the control group,but MMSE score appearants polarization. The cases are lower than the control group in Vis-vacuity,enomination,alculation,bstract,ttention,anguage,elay reminiscence,direction location and total score. Among the total, there are significant lower than the control group such as Vis-vacuity,enomination,alculation,bstract,elay reminiscence and total score(p<0.01). there are some diversity between the cases and the control group at the hippocampus MRS in left Cho( p=.012<0.05),AA(p=.008<0.01),right Cho (p= .033<0.05),AA (p=.034<0.05),of all the above contents, left NAA apparent significantly different between the cases and the control group. (2)According to insulin secretion function take C-peptide 0.3 as breakthrough,and then to divide the diabetes insulin secretion normal group and insulin secretion abnormal group, then make comparison with MOCA and MRS those two group, we found that there is no different in sex,age,education level about those two group,but they are diversity in orientation force with MoCA, there is also no different in MRS. (3)According to drug treatment condition(non treatment,drug treatment,insulin treatment) we found that there is no significant difference.Maybe this outcome have something with the cases selection,quantity,selection offset and so on.
Conclusion:there is a pristine cognition damage comparatively, and the cognition damage have something to do with blood glycometabolism and insulin secretion in diabetes, also it can reflected with implement MRS,we can found that there is abnormal metabolin in brain.
引文
[1] KnigH,AubertRE,Hemrna WH.Global burden of dibaetes,1995-2025:Prevalenee,numerieal estimates,and PorjeCtions. Dibaeets Care 1998;21(9):1414-31.
[2] WildS,RoglieG,GerenA,SieereR,KnigH.Global pervalence of dibaetes:estimates for the year 2000 and Projections for 2030.Dibaetes Care 2004:27(5):1047-53.
[3] Thomas VS,Dvaresh S,MacKnight C,Roewkood K.Estimating the Pervalence of dementia in elderly PeoPle:a comparison of the Canadian Study of Health and Agingnad National PoPulation Health Suvry approaehes.Int Psychogeriatr 2001;13Supp 1:169-75.
[4] Geldmaeher DS , Wllltehouse PJ.Evaluation of dementia.N Engl J Med 1996;335(5):330-6
[5] Pnaza F,Dtntrono A,Colaccco AM ,et al.Current epidemiology of mild congitive impairment and other Predementia syndromes.Am J Geriatr Psychiatry 2005;13(8):633-44
[6] Petesren RC,Stevens JC,Gnaguli M,Tnagalos EG.Cununnigs JL,DeKosky ST.PRACTICE PARAMETER:EARLY DETECTION OF DEMENTIA:MILD COGNITIV EIMPAIRMENT (AN EVIDENCE-BASEDREVIEW),Report of the Qualiy tSnatdards Subeonunittee of the Ameriean Academy of Neurology.Neuorlogy 2001;56:1133-42
[7]王德全,姜晓丹.老年痴呆患病率及危险因素调查.中国公共卫生2002;18(12):1498-9.
[8]费伟民,程夔,王玉梅,胡喜荣,孙才坚,高之旭.上海市卢湾区一个社区老年期痴呆患病率分析.四川精神卫生2001;14(1)l31-2
[9] Stewart R , Liolitsa D.Tpye 2 dibaetes mellitus , congitive impaimrent and demnetia.Dibaet Med 1999;16(2):93-112
[10] Strachan MW,Deary IJ,Ewing FM,Frier BM.1s type 2 dibaetes associated with an increased risk of congitive dysufnetion?A critieal review of Published studies.Dibaetes Caer 1997;20(3):438-45
[11] Bozoki A,Giordani B,Hedeibrink JL,Berent S,Foster NL.Mild congtiive impairments Prediet dementia in nondemented elderly patients with mimory loss.Acrh Neuorl 2001;58(3):411-6
[12] Petersen RC,Srniht GE,Waring SC,Ivnik RJ,Tnagalos EG,Koknlen E.Mild congitive lmpaimrent:clinical charaeterization and outcome.Arch Neurol 1999:56(3):303-8.
[13] Hnaninen T,Soninien H. Mild congtiive imPaimrent as an early sign of dementina.Duodecim 1999:115(4):381-8
[14] Friedrich MJ.Midl congitive impairment raises Alzheimer disease risk.Jama 1999;282(7):621-2
[15] Albert SM,Miehaels K,Pdailla M,Pelton G,Bell K,Marder K,Stner Y,Devnanad DP.Funetional significance of mild congitive impairment in elderly Patients wihtout a dementia diagnosis .Am J Geriatr psychiaty 1999;7(3):213-20
[16] Nasreddine ZS,PhillipsNA,Bedirian V,et al.The MontrealCogitive Assessment,MoCA:a brief screening tool for mild cognitive impairment.J Am Geriatr Soc,2005,53:695-699
[17]“蒙特利尔认知评估量表”在轻度认知功能损伤患者筛查中的应用王炜,王鲁宁,中华内科杂志2007年5月第46卷第5期Chin J Intern Med,May 2007,Vol 46,No.5
[18] Nasreddine ZS,Phillips NA,Bedirian V,et al.TheMontreal Cognitive Assessmnet,MoCA;a brief screening tool for mild cognitive impairment.J Am Geriatr Soc,2005,53:695-699
[19] Nasreddine ZS, Phillips NA,Bedirian V. The Montreal cognitive as-sessment (MOCA): A brief screening tool for mild cognitive impairment [J]. J Am Geriatr Soc,2005,53(4) :695一699
[20] Messier C,Awad N,Gagnon M.The relationships between atherosclerosis,heart disease,type 2 diabetes and dementia.Neurol Res,2004,26567-572
[21] Muranyi M,Fujioka M,He QP,et al.Diabetes activates cell death path-way after transient focal cerebral ischemia.Diabetes,2003,52:481-486.
[22] Schmidt RE,Dorsey DA,Beaudet LN,et al.Inhibition of sorbitol dehy-drogenase exacerbates autonomic neuropathy in rats with streptozotocin-induced diabetes.J Neuropathol Exp Neurol,2008,60:1153-1169
[23] Smiht MA,Taneda S,Richye P.et al.Advanced Maillard reaction and Porudcts areassociated with Alzheimer disease Phatology.Proc Nati Acad Sci U S A 1994;91(12):5710-4
[24] Vtiek MP Bhattaehayra K,Glendening JM,Stopa E,Vlassara H,Bueala R,Mnaogue K,Cermai A.Adavanced glyeation end Porduets conrtibute to anyloidosis in Alzheimer disease.Proc Natl Acad Sci U S A 1994:91(11):4766-70
[25] Saskai N,Fukatsu R,Tsuke U,Keta L.Advnaced glycation end products in Alzheime’s disease and other neurodegenerative diseases.AmJ phatol 2008:153(4):1149-55
[26] Frier BM. Hypoglycaemia and cognitive function in diabetes[J].In JClin PractSuppl,2001, 123: 30-37
[27] SmithD, AmielSA. Hypoglycaemia unawareness and the brain[J].Diabetologia,2002, 45(7): 949-958
[28] Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diahetes Trends Neurosci, 29(10)23:54Z-549
[29]唐伟,刘超(审校) 2型糖尿病与记忆功能卢正红(综述) (南京医科大学第一附属医院内分泌科,南京210029文章编号:1006-2084(2007)15-1156-03医学综述2007年8月第13卷第15期
[30] Schulingkamp RJ,Pagano TC,Hung D,et a1.Insulin receptors and insu-lin action in the brain: review and clinical implications. Neumsci Biobi-hav Rev,2008,24:855-872
[31] Craft S,Newcomer J,Kanne S,et al.Memory improvement fol-lowing induced hyperinsulinemia in Alzheimer’s disease [J].Neurobiol Aging, 1996 ,17(1): 123~130
[32] Park CR,Seeley RJ,Craft S,et al.Intracerebroventricular insulinenhances memory in a passive-avoidance task [J]. Physiol-Behav.2008,68(4): 509~514
[33] Gregg EW,Yaffe K,Cauley JA,Rolka DB,Blackwell TL,Narayan KM,Cummings ST.Is dibaetes associated with congitive impairment and congitive deecline among older women?Sutdy of Osteoporotic Factures Researeh Group.Arch Inten Med 2000;160(2):174一80
[34] HoyerS. Brain glucose and energymetabolism abnormalities in spo-radicAlzheimer disease. Cause and consequences: an update[ J].ExpGerontol ,2000 , 35(9-10): 1363-1372
[35] Ammon-Treiber S. Effects of opioid antagonists and morphine in ahippocampal hypoxia/ hypoglycemia model[J].Neuropharmacology,2005, 49(8): 1160-1169
[36] YonedaY, Yamamato S. Cerebral cortical laminarnecrosis on diffu-sion-weighted MRI in hypoglycaemic encephalopathy[ J].DiabetMed,2005, 22(8): 1098-1100.09 VassaraH, PalaceMR. Glycoxidation: the menace of diabetes andagingMtSinai JMed, 2003, 70(4): 232-241
[37] Duarte JM, Oliveira CR. Modification of adenosine A(1) and A(2A) receptor density in the hippocampus of streptozotocin-induceddiabetic rats[J].Neurochem Int,2006, 48(2): 144-150.
[38] Vignesh JP, Mohan V. Hypoglycaemia unawareness[ J].J AssocPhysicians India,2004, 52: 727-7321041-1044
[39] BiesselsGJ, Kappelle LJ. Increased risk ofAlzheimer’s disease inType II diabetes: insulin resistance of the brain or insulin-inducedamyloid pathology [ J].Biochem Soc Trans,2005, 33 (Pt 5)
[40] McCall AL, Cox DJ, Crean J, et al·A novel analytica method for assessing glucose variability: using CGMS in type 1 diabetes mellitus·Diabetes Technol Ther, 2006, 8(6): 644-653
[41] Stratton IM, AdlerAI, NeilHA, et al.Association of gly-caemia with macrovascular and microvascular complicationsofType 2 diabetes(UKPDS 35): prospective observationalstudy·BMJ, 2008, 321(7258): 405-412
[42] The Diabetes Control and Complication Trial ResearchGroup·The relationship of glycemic exposure(HbA1C) tothe risk of development and progression of retinopathy inthe diabetes control and complications trial·Diabetes,1995, 44(8): 968-983
[43] Risso A, Mercuri F, Quagliaro L, et al·Intemittent high glucose enhances apoptosis in human umbilicalvien endothe-lial cells in culture·Am J PhysiolEndocrinolMetab, 2001,281(5):E924-E930
[44] Monnier L,Mas E,Ginet C,et al·Activation of oxidative stress by acute glucose fluctuations compared with sustainedchronic hyperglycemia in patientswith type 2 diabetes·JA-MA 2006, 295(14): 1681-1687
[45] Burn E, ZoppiniG, ZamboniC, etal·Glucose instability is associated with a highlevel of circulating p-selectin·Diabe-tes Care, 2001, 24(9): 1685
[46] Nasreddine ZS,PhillipsNA,Bedirian V,et al.The MontrealCogitive Assessment,MoCA:a brief screening tool for mild cognitive impairment.J Am Geriatr Soc,2005,53:695-699
[47] Detre JA,Wang Z,Bogdan AR,et al.Regional variation in brain lactate in leigh syndrome by localized 1H magnetic resonance spectroscopey.Ann Neurol 1991;29:218-221
[48] Wind AW,Schellevis FG,Van Staveren G,et al.Limitations of the Mini-Mental State Examination in diagnosing dementia in general practice。Int J Geriatr Psychiatry,1997,12:101-108
[49] Collie A, Maruff P.The neuroPsyehology of Preelinical Alzheimer’s disease and mild cognitive imPairment . Neuroseience and Biobehavioral Reviews,2000,24:365
[50] NASREDDINE ZS, PHILLIPS NA, B6DIRIAN V, et al. The Montreal Cognitive Assessment(MoCA ):A Brief Screening Tool For Mild Cognitive Impairment[J]. J AmGeriatr Soc(S0001-8614),2005,53:695-699
[51] Whitmer R, Arenberg D. Type 2 diabetes and risk of cognitive impairment and dementia [J]. Cur Neurol Neurosci Rep,2007, 7(15):373-380
[52] Sasaki N, Fukatus R, Tsuzuki K, et al. Advanced glycation end products in Alzheimer′s disease and other neurodegenerative diseases[J]. Am J Pathol, 1998, 15(3):1149-1155
[53] Muranyi M,Fujioka M,He QP,et al.Diabetes activates cell death path-way after transient focal cerebral ischemia.Diabetes,2003,52:481-486 Neuropathol Exp Neurol,2008,60:1153-1169
[54] Biessels GJ.Cerebral complications of diabetes: clinical findings and pathogenetic mechanisms[J].Neth J Med,1999,54:35-45
[55] Allen KV,Frier BM,Strachan MW.The relationshipbetween type 2 diabetes and cognitive dysfunction:longitudinal studies and their methodological limitations[J].Eur J Pharmacol, 2004,490:169-175
[56] Ott A,Stolk RP,Hofman A,et al.Association of diabetes mellitus and dementia:the Rotterdam study[J].Diabetologia,1996,39:1392-1397
[57] Leibson CL,Rocca WA,Hauson VA,et al.Risk of dementia among persons with diabetes mellitus:a population-based cohort study[J].Am J Epidemiol, 1997,145:301-308
[58]卫炜,陆惠华,金贤,等.伴随病影响老年高血压患者认知功能和日常生活能力[J].高血压杂志,2005,13:779-782
[59] Gregg EW, Yaffe K, Cauley J A, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? [J]. Arch Inern Med, 2000, 160(8):174-180
[60] Logroscino G, Kang J H, Grodestein F. Prospective study otype 2 diabetes and cognitive decline in women aged 70-8 years[J]. BMJ, 2004, 23(6):328-341
[61] SkeberdisVA, Lan J, Zhang X,et al.Insulin promotes rapid delivery of N-methyl-D-asparate receptors to the cell surpace by exocytosis〔J〕.ProcNatlAcad SciUSA, 1998; 3561-6
[62] Byrne JH.Learning and memory: basic mechanisms.In: Squire LR, Bloom FE,McConnell SK,et al.eds.Fundamental neuroscience〔M〕. an Diego CA:Academic Press, 2003: 1276-98·
[63] Watson GS, Peskind ER, Asthana S,et al.Insulin increases CSF Ab42levels in normal older adults〔J〕.Neurology, 2003; 60(7): 1899-903
[64] Zhao LX, BruceT,TakashiM,etal.Insulin-degrading enzyme as a down-stream targetof insulin receptor signaling cascade; implication forAlzhei-mer′s disease intervention〔J〕.JNeurosc,i 2004; 24(10): 11120-6
[65] Zhong Z,Zhong MX,Haroutunian V. lnsulin degrading enzyme activity seleetively deereases in the hippocampal formation of ceases at high risk to develop Alzheimer’s disease.Neurobiology ofA ging,2007,28:824-830
[66] Xie L,Helmerhoret E,Taddei K,etal.Alzheimer,beta-myloid PePtides comPete for insulin binding to the insulin reeePtor .Neurosei,2002,22(10):RC221
[67] SkeberdisV.A,LanJ.lnsulin Promotes raPid delivery of N-methyl-D-aspartate recePtors to the cell stirface by exoeytosis. Proc Natl Acad Sci USA,2001,98(6):3561-3566
[68] Tierney M,Szalai J,Snoww,etal. Predieation of Probable Patients. A Prospective longitudinal study. Neurology,1996,46:661-665
[69] Sara E YOung,Arch G Mainons,Mark Camemolla.HyPerinsulinemia and cognitive deeline in a Middle-Agedcohort. Diabetes Care,2006,79(12):2688
[70] Luehsinger JA,Tang MX,Shea S,etal. HyPerinsulinemia and risk of Alzheimer disease. Neurology,2004,63:1187-1192
[71] Benediet C,Hallsehmid M,Sehultes B,etal.Intranasal Insulin to ImProve Memory Funetion in Humans. Neuroenderinology,2007,86:136-142
[72] SchubertM, BrazilDP, BurksDJ,etal.Insulin receptor substrate22 deficiency impairs brain growth and promotes tau phosphorylation〔J〕.J Neurosc,i 2003; 23(7): 7084-92
[73] Gasparini L, NetzerWJ, Greengard P,et al.Does insulin dysfunction play a role inAlzheimer′sdisease〔J〕? TrendsPharmacolSc,i 2002; 23(2): 288-93
[74] HoyerS. Brain glucose and energymetabolism abnormalities in spo-radicAlzheimer disease. Cause and consequences: an update[ J].ExpGerontol,2000,35(9-10): 1363-1372.
[75] Steen E, Terry BM, Rivera EJ,et al.Impaired insulin and insulin likegrowth factor expression and signaling mechanisms in Alzheimer′s dis-ease-is this type 3 diabetes〔J〕JAlzheimer′s Dis, 2005; 7(1): 63-80
[76] 52Lester-Coll N, Rivera EJ, Soscia SJ,et al.Intracerebral streptozotocinmodel of type 3 diabetes: relevance to sporadicAlzheimer′s disease〔J〕.JAlzheimersDis, 2006; 1(1): 13-33·
[77] Basu R, BredaE,ObergAL,etal.Mechanismsof the age associated dete-rioration in glucose tolerance: contribution of alterations in insulin secre-tion, action, and clearance〔J〕.Diabetes, 2003; 52(7): 1738-45
[78] BasuR,ManCD,CampioniM,etal.Effectsofage and sex on postprandi-al glucosemetabolism: differences in glucose turnover, insulin secretion,insulin action, and hepatic insulin extraction〔J〕.Diabetes, 2006; 55(7):2001-4·
[79] Basu R, BredaE,ObergAL,etal.Mechanismsof the age associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance〔J〕.Diabetes, 2003; 52(7): 1738-45
[80] BasuR,ManCD,CampioniM,etal.Effectsofage and sex on postprandial glucosemetabolism: differences in glucose turnover, insulin secretion,insulin action, and hepatic insulin extraction〔J〕.Diabetes, 2006; 55(7):2001-4·
[81] Watson GS, Cholerton BA, RegerMA,etal.Preserved cognition in patientswith earlyAlzheimer disease and amnesticmild cognitive impairment during treatment with rosiglitazone〔J〕.Am J Geriatr Psychiat,2005; 13(9): 950-58·
[82] Kalaria RN.The role of cerebral ischemia in Alzheimer’s disease .NeurobiolAging,2000,21:321-330
[83] Lebovitz HE. Insulin resistanee: definition and consequences. ExP Clin Endoerinol Diabetes,2001,109:135-148
[84] Frederrick BD, Lyoo IK, Satlin A, et al. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer s disease. Prog Neuropsychopharmacol Biol Psychiatry, 2004,28(8):1313-1322.
[85] Luchsinger JA, Tang MX, Shea S, et al. Hyperinsulinemia and risk of Alzheimer disease. Neurology, 2004,63(7):1187-1192.
[86] LiZG, ZhangW,GrunbergerG,etal.Hippocampalneuronal apoptosisin type 1 diabetes〔J〕.Brain Res, 2002; 946(2): 221-31
[87] Zhao LX, BruceT,TakashiM,etal.Insulin-degrading enzyme as a down stream targetof insulin receptor signaling cascade; implication forAlzheimer′s disease intervention〔J〕.JNeurosc,i 2004; 24(10): 11120-6
[88] chubertM, BrazilDP, BurksDJ,etal.Insulin receptor substrate22 de-ficiency impairs brain growth and promotes tau phosphorylation〔J〕.JNeurosc,i 2003; 23(7): 7084-92·
[89] iZG, ZhangW,GrunbergerG,etal.Hippocampalneuronal apoptosisin type 1 diabetes〔J〕.Brain Res, 2002; 946(2): 221-31
[90] llen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest, 2005,115(5):1111-1119.
[91] Watson GS, Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer s disease. Eur J Pharmacol, 2004,490(1-3):97-113
[92] raft S,Watoson GS. Insulin and neurodegenerative disease:shared and spceific mechanisms.LaneetNeurol,2004,3:169-178
[93] asparini L, NetzerWJ, Greengard P,etal.Does insulin dysfunction play a role inAlzheimer’s disease〔J〕TrendsPharmacolSc,i 2002; 23(2): 288-93·
[94] cGeerPL, Rogers J, McGeerEG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last12years[ J]. J Alzheimers Dis,2006,9(3Suppl): S271-S276
[2] WildS,RoglieG,GerenA,SieereR,KnigH.Global pervalence of dibaetes:estimates for the year 2000 and Projections for 2030.Dibaetes Care 2004:27(5):1047-53.
[3] Thomas VS,Dvaresh S,MacKnight C,Roewkood K.Estimating the Pervalence of dementia in elderly PeoPle:a comparison of the Canadian Study of Health and Agingnad National PoPulation Health Suvry approaehes.Int Psychogeriatr 2001;13Supp 1:169-75.
[4] Geldmaeher DS , Wllltehouse PJ.Evaluation of dementia.N Engl J Med 1996;335(5):330-6
[5] Pnaza F,Dtntrono A,Colaccco AM ,et al.Current epidemiology of mild congitive impairment and other Predementia syndromes.Am J Geriatr Psychiatry 2005;13(8):633-44
[6] Petesren RC,Stevens JC,Gnaguli M,Tnagalos EG.Cununnigs JL,DeKosky ST.PRACTICE PARAMETER:EARLY DETECTION OF DEMENTIA:MILD COGNITIV EIMPAIRMENT (AN EVIDENCE-BASEDREVIEW),Report of the Qualiy tSnatdards Subeonunittee of the Ameriean Academy of Neurology.Neuorlogy 2001;56:1133-42
[7]王德全,姜晓丹.老年痴呆患病率及危险因素调查.中国公共卫生2002;18(12):1498-9.
[8]费伟民,程夔,王玉梅,胡喜荣,孙才坚,高之旭.上海市卢湾区一个社区老年期痴呆患病率分析.四川精神卫生2001;14(1)l31-2
[9] Stewart R , Liolitsa D.Tpye 2 dibaetes mellitus , congitive impaimrent and demnetia.Dibaet Med 1999;16(2):93-112
[10] Strachan MW,Deary IJ,Ewing FM,Frier BM.1s type 2 dibaetes associated with an increased risk of congitive dysufnetion?A critieal review of Published studies.Dibaetes Caer 1997;20(3):438-45
[11] Bozoki A,Giordani B,Hedeibrink JL,Berent S,Foster NL.Mild congtiive impairments Prediet dementia in nondemented elderly patients with mimory loss.Acrh Neuorl 2001;58(3):411-6
[12] Petersen RC,Srniht GE,Waring SC,Ivnik RJ,Tnagalos EG,Koknlen E.Mild congitive lmpaimrent:clinical charaeterization and outcome.Arch Neurol 1999:56(3):303-8.
[13] Hnaninen T,Soninien H. Mild congtiive imPaimrent as an early sign of dementina.Duodecim 1999:115(4):381-8
[14] Friedrich MJ.Midl congitive impairment raises Alzheimer disease risk.Jama 1999;282(7):621-2
[15] Albert SM,Miehaels K,Pdailla M,Pelton G,Bell K,Marder K,Stner Y,Devnanad DP.Funetional significance of mild congitive impairment in elderly Patients wihtout a dementia diagnosis .Am J Geriatr psychiaty 1999;7(3):213-20
[16] Nasreddine ZS,PhillipsNA,Bedirian V,et al.The MontrealCogitive Assessment,MoCA:a brief screening tool for mild cognitive impairment.J Am Geriatr Soc,2005,53:695-699
[17]“蒙特利尔认知评估量表”在轻度认知功能损伤患者筛查中的应用王炜,王鲁宁,中华内科杂志2007年5月第46卷第5期Chin J Intern Med,May 2007,Vol 46,No.5
[18] Nasreddine ZS,Phillips NA,Bedirian V,et al.TheMontreal Cognitive Assessmnet,MoCA;a brief screening tool for mild cognitive impairment.J Am Geriatr Soc,2005,53:695-699
[19] Nasreddine ZS, Phillips NA,Bedirian V. The Montreal cognitive as-sessment (MOCA): A brief screening tool for mild cognitive impairment [J]. J Am Geriatr Soc,2005,53(4) :695一699
[20] Messier C,Awad N,Gagnon M.The relationships between atherosclerosis,heart disease,type 2 diabetes and dementia.Neurol Res,2004,26567-572
[21] Muranyi M,Fujioka M,He QP,et al.Diabetes activates cell death path-way after transient focal cerebral ischemia.Diabetes,2003,52:481-486.
[22] Schmidt RE,Dorsey DA,Beaudet LN,et al.Inhibition of sorbitol dehy-drogenase exacerbates autonomic neuropathy in rats with streptozotocin-induced diabetes.J Neuropathol Exp Neurol,2008,60:1153-1169
[23] Smiht MA,Taneda S,Richye P.et al.Advanced Maillard reaction and Porudcts areassociated with Alzheimer disease Phatology.Proc Nati Acad Sci U S A 1994;91(12):5710-4
[24] Vtiek MP Bhattaehayra K,Glendening JM,Stopa E,Vlassara H,Bueala R,Mnaogue K,Cermai A.Adavanced glyeation end Porduets conrtibute to anyloidosis in Alzheimer disease.Proc Natl Acad Sci U S A 1994:91(11):4766-70
[25] Saskai N,Fukatsu R,Tsuke U,Keta L.Advnaced glycation end products in Alzheime’s disease and other neurodegenerative diseases.AmJ phatol 2008:153(4):1149-55
[26] Frier BM. Hypoglycaemia and cognitive function in diabetes[J].In JClin PractSuppl,2001, 123: 30-37
[27] SmithD, AmielSA. Hypoglycaemia unawareness and the brain[J].Diabetologia,2002, 45(7): 949-958
[28] Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diahetes Trends Neurosci, 29(10)23:54Z-549
[29]唐伟,刘超(审校) 2型糖尿病与记忆功能卢正红(综述) (南京医科大学第一附属医院内分泌科,南京210029文章编号:1006-2084(2007)15-1156-03医学综述2007年8月第13卷第15期
[30] Schulingkamp RJ,Pagano TC,Hung D,et a1.Insulin receptors and insu-lin action in the brain: review and clinical implications. Neumsci Biobi-hav Rev,2008,24:855-872
[31] Craft S,Newcomer J,Kanne S,et al.Memory improvement fol-lowing induced hyperinsulinemia in Alzheimer’s disease [J].Neurobiol Aging, 1996 ,17(1): 123~130
[32] Park CR,Seeley RJ,Craft S,et al.Intracerebroventricular insulinenhances memory in a passive-avoidance task [J]. Physiol-Behav.2008,68(4): 509~514
[33] Gregg EW,Yaffe K,Cauley JA,Rolka DB,Blackwell TL,Narayan KM,Cummings ST.Is dibaetes associated with congitive impairment and congitive deecline among older women?Sutdy of Osteoporotic Factures Researeh Group.Arch Inten Med 2000;160(2):174一80
[34] HoyerS. Brain glucose and energymetabolism abnormalities in spo-radicAlzheimer disease. Cause and consequences: an update[ J].ExpGerontol ,2000 , 35(9-10): 1363-1372
[35] Ammon-Treiber S. Effects of opioid antagonists and morphine in ahippocampal hypoxia/ hypoglycemia model[J].Neuropharmacology,2005, 49(8): 1160-1169
[36] YonedaY, Yamamato S. Cerebral cortical laminarnecrosis on diffu-sion-weighted MRI in hypoglycaemic encephalopathy[ J].DiabetMed,2005, 22(8): 1098-1100.09 VassaraH, PalaceMR. Glycoxidation: the menace of diabetes andagingMtSinai JMed, 2003, 70(4): 232-241
[37] Duarte JM, Oliveira CR. Modification of adenosine A(1) and A(2A) receptor density in the hippocampus of streptozotocin-induceddiabetic rats[J].Neurochem Int,2006, 48(2): 144-150.
[38] Vignesh JP, Mohan V. Hypoglycaemia unawareness[ J].J AssocPhysicians India,2004, 52: 727-7321041-1044
[39] BiesselsGJ, Kappelle LJ. Increased risk ofAlzheimer’s disease inType II diabetes: insulin resistance of the brain or insulin-inducedamyloid pathology [ J].Biochem Soc Trans,2005, 33 (Pt 5)
[40] McCall AL, Cox DJ, Crean J, et al·A novel analytica method for assessing glucose variability: using CGMS in type 1 diabetes mellitus·Diabetes Technol Ther, 2006, 8(6): 644-653
[41] Stratton IM, AdlerAI, NeilHA, et al.Association of gly-caemia with macrovascular and microvascular complicationsofType 2 diabetes(UKPDS 35): prospective observationalstudy·BMJ, 2008, 321(7258): 405-412
[42] The Diabetes Control and Complication Trial ResearchGroup·The relationship of glycemic exposure(HbA1C) tothe risk of development and progression of retinopathy inthe diabetes control and complications trial·Diabetes,1995, 44(8): 968-983
[43] Risso A, Mercuri F, Quagliaro L, et al·Intemittent high glucose enhances apoptosis in human umbilicalvien endothe-lial cells in culture·Am J PhysiolEndocrinolMetab, 2001,281(5):E924-E930
[44] Monnier L,Mas E,Ginet C,et al·Activation of oxidative stress by acute glucose fluctuations compared with sustainedchronic hyperglycemia in patientswith type 2 diabetes·JA-MA 2006, 295(14): 1681-1687
[45] Burn E, ZoppiniG, ZamboniC, etal·Glucose instability is associated with a highlevel of circulating p-selectin·Diabe-tes Care, 2001, 24(9): 1685
[46] Nasreddine ZS,PhillipsNA,Bedirian V,et al.The MontrealCogitive Assessment,MoCA:a brief screening tool for mild cognitive impairment.J Am Geriatr Soc,2005,53:695-699
[47] Detre JA,Wang Z,Bogdan AR,et al.Regional variation in brain lactate in leigh syndrome by localized 1H magnetic resonance spectroscopey.Ann Neurol 1991;29:218-221
[48] Wind AW,Schellevis FG,Van Staveren G,et al.Limitations of the Mini-Mental State Examination in diagnosing dementia in general practice。Int J Geriatr Psychiatry,1997,12:101-108
[49] Collie A, Maruff P.The neuroPsyehology of Preelinical Alzheimer’s disease and mild cognitive imPairment . Neuroseience and Biobehavioral Reviews,2000,24:365
[50] NASREDDINE ZS, PHILLIPS NA, B6DIRIAN V, et al. The Montreal Cognitive Assessment(MoCA ):A Brief Screening Tool For Mild Cognitive Impairment[J]. J AmGeriatr Soc(S0001-8614),2005,53:695-699
[51] Whitmer R, Arenberg D. Type 2 diabetes and risk of cognitive impairment and dementia [J]. Cur Neurol Neurosci Rep,2007, 7(15):373-380
[52] Sasaki N, Fukatus R, Tsuzuki K, et al. Advanced glycation end products in Alzheimer′s disease and other neurodegenerative diseases[J]. Am J Pathol, 1998, 15(3):1149-1155
[53] Muranyi M,Fujioka M,He QP,et al.Diabetes activates cell death path-way after transient focal cerebral ischemia.Diabetes,2003,52:481-486 Neuropathol Exp Neurol,2008,60:1153-1169
[54] Biessels GJ.Cerebral complications of diabetes: clinical findings and pathogenetic mechanisms[J].Neth J Med,1999,54:35-45
[55] Allen KV,Frier BM,Strachan MW.The relationshipbetween type 2 diabetes and cognitive dysfunction:longitudinal studies and their methodological limitations[J].Eur J Pharmacol, 2004,490:169-175
[56] Ott A,Stolk RP,Hofman A,et al.Association of diabetes mellitus and dementia:the Rotterdam study[J].Diabetologia,1996,39:1392-1397
[57] Leibson CL,Rocca WA,Hauson VA,et al.Risk of dementia among persons with diabetes mellitus:a population-based cohort study[J].Am J Epidemiol, 1997,145:301-308
[58]卫炜,陆惠华,金贤,等.伴随病影响老年高血压患者认知功能和日常生活能力[J].高血压杂志,2005,13:779-782
[59] Gregg EW, Yaffe K, Cauley J A, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? [J]. Arch Inern Med, 2000, 160(8):174-180
[60] Logroscino G, Kang J H, Grodestein F. Prospective study otype 2 diabetes and cognitive decline in women aged 70-8 years[J]. BMJ, 2004, 23(6):328-341
[61] SkeberdisVA, Lan J, Zhang X,et al.Insulin promotes rapid delivery of N-methyl-D-asparate receptors to the cell surpace by exocytosis〔J〕.ProcNatlAcad SciUSA, 1998; 3561-6
[62] Byrne JH.Learning and memory: basic mechanisms.In: Squire LR, Bloom FE,McConnell SK,et al.eds.Fundamental neuroscience〔M〕. an Diego CA:Academic Press, 2003: 1276-98·
[63] Watson GS, Peskind ER, Asthana S,et al.Insulin increases CSF Ab42levels in normal older adults〔J〕.Neurology, 2003; 60(7): 1899-903
[64] Zhao LX, BruceT,TakashiM,etal.Insulin-degrading enzyme as a down-stream targetof insulin receptor signaling cascade; implication forAlzhei-mer′s disease intervention〔J〕.JNeurosc,i 2004; 24(10): 11120-6
[65] Zhong Z,Zhong MX,Haroutunian V. lnsulin degrading enzyme activity seleetively deereases in the hippocampal formation of ceases at high risk to develop Alzheimer’s disease.Neurobiology ofA ging,2007,28:824-830
[66] Xie L,Helmerhoret E,Taddei K,etal.Alzheimer,beta-myloid PePtides comPete for insulin binding to the insulin reeePtor .Neurosei,2002,22(10):RC221
[67] SkeberdisV.A,LanJ.lnsulin Promotes raPid delivery of N-methyl-D-aspartate recePtors to the cell stirface by exoeytosis. Proc Natl Acad Sci USA,2001,98(6):3561-3566
[68] Tierney M,Szalai J,Snoww,etal. Predieation of Probable Patients. A Prospective longitudinal study. Neurology,1996,46:661-665
[69] Sara E YOung,Arch G Mainons,Mark Camemolla.HyPerinsulinemia and cognitive deeline in a Middle-Agedcohort. Diabetes Care,2006,79(12):2688
[70] Luehsinger JA,Tang MX,Shea S,etal. HyPerinsulinemia and risk of Alzheimer disease. Neurology,2004,63:1187-1192
[71] Benediet C,Hallsehmid M,Sehultes B,etal.Intranasal Insulin to ImProve Memory Funetion in Humans. Neuroenderinology,2007,86:136-142
[72] SchubertM, BrazilDP, BurksDJ,etal.Insulin receptor substrate22 deficiency impairs brain growth and promotes tau phosphorylation〔J〕.J Neurosc,i 2003; 23(7): 7084-92
[73] Gasparini L, NetzerWJ, Greengard P,et al.Does insulin dysfunction play a role inAlzheimer′sdisease〔J〕? TrendsPharmacolSc,i 2002; 23(2): 288-93
[74] HoyerS. Brain glucose and energymetabolism abnormalities in spo-radicAlzheimer disease. Cause and consequences: an update[ J].ExpGerontol,2000,35(9-10): 1363-1372.
[75] Steen E, Terry BM, Rivera EJ,et al.Impaired insulin and insulin likegrowth factor expression and signaling mechanisms in Alzheimer′s dis-ease-is this type 3 diabetes〔J〕JAlzheimer′s Dis, 2005; 7(1): 63-80
[76] 52Lester-Coll N, Rivera EJ, Soscia SJ,et al.Intracerebral streptozotocinmodel of type 3 diabetes: relevance to sporadicAlzheimer′s disease〔J〕.JAlzheimersDis, 2006; 1(1): 13-33·
[77] Basu R, BredaE,ObergAL,etal.Mechanismsof the age associated dete-rioration in glucose tolerance: contribution of alterations in insulin secre-tion, action, and clearance〔J〕.Diabetes, 2003; 52(7): 1738-45
[78] BasuR,ManCD,CampioniM,etal.Effectsofage and sex on postprandi-al glucosemetabolism: differences in glucose turnover, insulin secretion,insulin action, and hepatic insulin extraction〔J〕.Diabetes, 2006; 55(7):2001-4·
[79] Basu R, BredaE,ObergAL,etal.Mechanismsof the age associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance〔J〕.Diabetes, 2003; 52(7): 1738-45
[80] BasuR,ManCD,CampioniM,etal.Effectsofage and sex on postprandial glucosemetabolism: differences in glucose turnover, insulin secretion,insulin action, and hepatic insulin extraction〔J〕.Diabetes, 2006; 55(7):2001-4·
[81] Watson GS, Cholerton BA, RegerMA,etal.Preserved cognition in patientswith earlyAlzheimer disease and amnesticmild cognitive impairment during treatment with rosiglitazone〔J〕.Am J Geriatr Psychiat,2005; 13(9): 950-58·
[82] Kalaria RN.The role of cerebral ischemia in Alzheimer’s disease .NeurobiolAging,2000,21:321-330
[83] Lebovitz HE. Insulin resistanee: definition and consequences. ExP Clin Endoerinol Diabetes,2001,109:135-148
[84] Frederrick BD, Lyoo IK, Satlin A, et al. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer s disease. Prog Neuropsychopharmacol Biol Psychiatry, 2004,28(8):1313-1322.
[85] Luchsinger JA, Tang MX, Shea S, et al. Hyperinsulinemia and risk of Alzheimer disease. Neurology, 2004,63(7):1187-1192.
[86] LiZG, ZhangW,GrunbergerG,etal.Hippocampalneuronal apoptosisin type 1 diabetes〔J〕.Brain Res, 2002; 946(2): 221-31
[87] Zhao LX, BruceT,TakashiM,etal.Insulin-degrading enzyme as a down stream targetof insulin receptor signaling cascade; implication forAlzheimer′s disease intervention〔J〕.JNeurosc,i 2004; 24(10): 11120-6
[88] chubertM, BrazilDP, BurksDJ,etal.Insulin receptor substrate22 de-ficiency impairs brain growth and promotes tau phosphorylation〔J〕.JNeurosc,i 2003; 23(7): 7084-92·
[89] iZG, ZhangW,GrunbergerG,etal.Hippocampalneuronal apoptosisin type 1 diabetes〔J〕.Brain Res, 2002; 946(2): 221-31
[90] llen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest, 2005,115(5):1111-1119.
[91] Watson GS, Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer s disease. Eur J Pharmacol, 2004,490(1-3):97-113
[92] raft S,Watoson GS. Insulin and neurodegenerative disease:shared and spceific mechanisms.LaneetNeurol,2004,3:169-178
[93] asparini L, NetzerWJ, Greengard P,etal.Does insulin dysfunction play a role inAlzheimer’s disease〔J〕TrendsPharmacolSc,i 2002; 23(2): 288-93·
[94] cGeerPL, Rogers J, McGeerEG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last12years[ J]. J Alzheimers Dis,2006,9(3Suppl): S271-S276